PHYSICIAN PORTAL

Physician Interviews

SLT and the Glaucoma Surgeon – Interview with Tarek Shaarawy, MD (Switzerland)

Not only can SLT achieve sustained IOP reduction for the majority of your glaucoma patients, but it has also been hypothesized to improve the prognosis of glaucoma surgery as compared to long-term medication use.

Predicting Success with SLT – Interview with Cindy L. Huntik, BSc, MD, PhD, FRCS(C) (Canada)

Now that more physicians and patients have access to SLT, it is important to understand how this modality best fits into the management of patients with glaucoma. Since not all patients respond equally to SLT, isolating the factors that can help to determine the likelihood that a patient will respond successfully to treatment with SLT is an important step in glaucoma management.

SLT in the Glaucoma Treatment Armamentarium – Interview with Roberto Cararssa, MD (Italy)

Long-term control of intraocular pressure (IOP) is key to minimizing the ocular damage that eventually occurs in glaucoma patients. The effects of traditional anti-glaucoma eyedrops are short-lived and therefore require diligent, long-term use. Even argon laser trabeculoplasty (ALT), which is known to deliver effective results, starts to lose efficacy within several years. In contrast, selective laser trabeculoplasty (SLT) delivers effective IOP reduction that lasts far longer than any other treatment.

Achieving Versatility in Glaucoma Management – Interview with Shlomo Melamed, MD (Israel)

The effectiveness of SLT in treating open-angle glaucoma and ocular hypertension is well established. SLT can also be used to effectively treat pseudoexfoliation glaucoma, pigmentary glaucoma, normal tension glaucoma, pseudophakic glaucoma, and angle-closure glaucoma post-iridotomy – making it an extremely versatile tool in the glaucoma treatment armamentarium.

The Mechanism of Action of SLT – Interview with K Sheng Lim, MB ChB, MD, FRCOphth (UK)

A number of theories have been proposed regarding the mechanism of action of Selective Laser Trabeculoplasty (SLT). Whilst SLT has been shown to achieve a similar therapeutic effect as Argon Laser Trabeculoplasty (ALT) in the treatment of glaucoma, the mechanical and biological effects differ markedly. Most importantly, SLT is able to achieve the desired therapeutic effect without the coagulative damage caused by ALT. Watch the video interview with Mr. Lim to learn more.

SLT: The Standard of Care for Glaucoma – Interview with Robert Paden, MD (USA)

One of the biggest advantages of SLT is that, in addition to being an effectiveapproach for first-line glaucoma treatment, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, it also eliminates the compliance issues and ongoing expense of medications for the patient.

SLT and the Refractive Surgeon – Interview with Matthias Maus, MD

The glaucoma medications used to control the IOP of refractive patients often add to the blurred vision experienced by these patients on a daily basis. This leaves the refractive surgeon with the frustrating task of correcting refractive error without being able to eliminate a key contributor to the problem. In this Video interview, Matahias Maus, MD, one of Germany’s leading refractive surgeons, addresses how SLT the role of SLT as an effective first-line glaucoma treatment for these patients, whilst eliminating the need for troublesome medications.

Bringing Down the Cost of Glaucoma Treatment with SLT – Interview with Randy E. Craven, MD (USA)

One of the biggest advantages of SLT is that, in addition to being an effective approach for first-line glaucoma treatment, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, it has also been found to be a more economical approach when compared to topical medications. In this video interview Randy E. Craven, MD, spotlights the many financial benefits of SLT for the patient — and for the wider healthcare system.

SLT Treatment Protocol – Interview with Lawrence F. Jindra, MD (USA)

With one of the world’s largest SLT case studies – more than 4500 eyes treated – Lawrence F. Jindra is considered to be an expert in the use of SLT to treat glaucoma. In this video interview, Dr. Jindra highlights how to achieve the best results when using SLT to treat various types of glaucoma, and on various patient types.

SLT as a Primary Therapy for Glaucoma – Interview with Andrew G. Iwach, MD (USA)

According to glaucoma expert Andrew G. Iwach, MD, at the ASCRS 2013 in San Francisco, he and his colleagues have known for a long time that SLT delivers better IOP-reducing results when used as primary therapy.

SLT as Primary, Adjunct and Alternative Therapy for Glaucoma – Interview with Andrew G. Iwach, MD (USA)

SLT is a highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail.

Webinars

AAO 2013
Earlier is Better with SLT
Andrew G. Iwach, MD
Glaucoma Center of San Francisco, USA

SLT is a highly effective first-line therapy. It is also effective as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail. Most importantly, SLT enables you to take control of your patients’ glaucoma treatment without the compliance issues and side effects associated with drug therapy.

AAO 2013
SLT is Not ALT Lite
Andrew G. Iwach, MD
Glaucoma Center of San Francisco, USA

SLT achieves the desired therapeutic effect whilst avoiding the coagulative damage that is associated with argon laser trabeculoplasty (ALT). Unlike ALT, it achieves a sustained IOP reduction over the long-term and can be repeated, if needed.

AAO 2013
The Glaucoma Compliance Conundrum
Andrew G. Iwach, MD
Glaucoma Center of San Francisco, USA

A highly effective primary therapy option, especially in non-compliant patients or in patients who have difficulty taking medications, SLT can also be used to reduce the number of medications required to control IOP – and thereby free your patients from the compliance issues and side effects associated with medications.

AAO 2012
The Efficacy of SLT for Angle Closure Glaucoma
Tin Aung, PhD
Singapore National Eye Centre, National University of Singapore

SLT has ben shown to be effective in lowering the IOP in patients with PAC and PACG after iridotomy.

AAO 2012
SLT: Current Role in Glaucoma Management
Andrew Iwach, MD
Glaucoma Center of San Francisico, USA

SLT is a highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail.

SLT Clinical Footage

SLT Clinical Footage: Heavily-Pigmented Trabeculum
Source: Prof. Philippe Denis (France)

It is important to note that less energy is required when performing SLT on patients with a heavily pigmented trabeculum. In this case study, extensive mini-bubble formation was noted at the commencement of SLT treatment, indicating that the energy level was too high. The energy level was consequently decreased to be just below the threshold level for bubble formation.

SLT Clinical Footage: Irregular Pigmentation
Source: Prof. Philippe Denis (France)

Tip: Always ensure that focus is maintained on the target tissue, and not on the laser beam spot. In addition, the treatment beam should cover the central part of the trabecular meshwork, where pigmentation is maximal.

SLT Clinical Footage: Narrow Angle Glaucoma
Source: Prof. Philippe Denis (France)

When performing SLT on patients with narrow angles, visibility is reduced compared to normal angles. It is important to ensure the patient looks toward the mirror in order to improve visibility. In addition, the laser treatment beam must be applied closer to the iris base, but without touching it.

SLT Clinical Footage: Treatment Protocol
Source: Prof. Philippe Denis (France)

Treatment is undertaken in single shot mode, with consecutive but not overlapping spots placed over the interior half of the trabecular meshwork. To determine the optimal level of energy for each patient, the energy level is gradually increased until the threshold energy level for mini-bubble information is observed, or decreased if bubble formation is noted.